Why the study?
Do metabolites from Senecio nutans and their oximes inhibit ACE activity and reduce vascular contractility in preclinical models?
Do metabolites from Senecio nutans and their oximes inhibit ACE activity and reduce vascular contractility in preclinical models?
Oxime derivatives of metabolites from Senecio nutans demonstrate potent ACE inhibitory activity and reduce vascular contractility in preclinical models, suggesting potential as novel antihypertensive agents.
These plant-derived oximes have no immediate clinical application; leaves open a hypothesis-generating pathway.
Angiotensin-Converting Enzyme (ACE) plays a pivotal role in the renin–angiotensin system, modulating blood pressure and electrolyte homeostasis by deactivating bradykinin and activating angiotensin II. Metabolites from Senecio nutans (1 and 3), a plant indigenous to the Andean region of the Atacama Desert, and their respective oximes, 2 and 4, were subjected to molecular docking analysis, employing six ACE crystal structures. ACE activity assays revealed that oximes exhibited superior inhibitory effects compared to metabolites. Among the compounds investigated, 2 emerged as the most potent ACE inhibitor (2 = 11.5 μM and 4 = 13.4 μM). The vascular contractile response to Angiotensin I showed significant (p < 0.05) reductions in Ang I contraction with 2, 3, and 4 (97 ± 6%, 81 ± 6%, 81 ± 3% compared to control), while 1 exhibited no such effect. These results reinforce the potential of 2 as a promising ACE inhibitor and highlight its impact on vascular contractility. As such, it is a promising candidate for ACE inhibition and hypertension treatment.
No takes yet. Share an insight, caveat, or question.
Palacios et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: